cagrisema semaglutide cagrilintide phase 3 results 2024 2025 Novo's disappoint analysts, sending stock tumbling - MM+M Cagrilintide–semaglutide (CagriSema) versus semaglutide or

Jones B, McGlone ER, Fang Z, Pickford P, Corra IR, Jr., Oishi A, Jockers R, Inoue A, Kumar S, Grlitz F, et al: Genetic and biased agonist-mediated reductions in -arrestin recruitment prolong cAMP signaling at glucagon family receptors

Lillys Phase II clinical trial results, published in the New England Journal of Medicine, demonstrate that orforglipron achieved up to a 14.7% mean weight reduction at 36 weeks in adults with obesity or overweight

The gradual dose escalation recommended by the FDA balances efficacy with tolerability, but it means that full appetite suppression may not occur until higher doses are reached

doi: 10.1016/j.amjmed.2025.01.021 5 NauckMAMeierJJ